INTRODUCTION
This Amendment No. 5 toSchedule 13E-3 amends and supplements the Schedule13E-3 originally filed with the Securities and Exchange Commission (“SEC”) on October 16, 2019, Amendment No. 1 thereto filed with the SEC on October 25, 2019, Amendment No. 2 thereto filed with the SEC on October 28, 2019, Amendment No. 3 thereto filed with the SEC on November 15, 2019, and Amendment No. 4 thereto filed with the SEC on January 31, 2020 (together with any amendments and supplements thereto and the exhibits thereto and hereto, this “Schedule13E-3”)and relates to a Share Repurchase Program (the “Program”) by SunLink Health Systems, Inc. (“SunLink” or the “Company”). At the recommendation of management of the Company, SunLink’s Board of Directors (the “Board”) approved and has implemented the Program, which provides for the repurchase of up to $750,000 of the Company’s common shares, no par value (the “Shares”) from time to time, at prevailing market prices through open market transactions pursuant toRule 10b5-1 and Rule10b-18 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”). The purpose of the Program is to return capital to shareholders who wish to sell their shares, to increase the liquidity of the market for the shares during the pendency of the Program, and allow holders of the shares a purely voluntary opportunity to receive a return of some or all of their investment, in a tax efficient manner, if they so elect.
The Program and purchases thereunder possibly could have the effect of reducing the number of holders of record of shares, which, depending on the extent of the reduction, could permit the Company to deregister the shares under the Exchange Act and cease being a public reporting company (collectively, “Deregistration”). The Company cannot predict whether purchases of shares pursuant to the Program will result in, or are reasonably likely to result in, a reduction in the number of holders of record that would be sufficient to allow Deregistration. However, purchases of shares pursuant to the Program may result in a reduction in the number of shareholders of record such that the Company would be able to deregister. In such event, management might recommend and the Board might approve Deregistration if they conclude Deregistration is in the best interests of the Company. Management and the Board each currently believe that Deregistration could result in significant cost savings to the Company. As the Program may result in a potential Deregistration, the Company is treating the Program as a “purchase” within the meaning of Rule 13e-3 and has filed this Schedule13E-3 (of which a Notice of Share Repurchase Program dated October 28, 2019 (the “Notice”) is an exhibit) with the SEC and is providing its shareholders with the same information as is required in a going private transaction intended to or which could reasonably be expected to result in Deregistration.
The information contained in the Notice, a copy of which is attached to this Schedule13E-3 as Exhibit (a)(3)(A) is incorporated herein by reference in response to all of the items of this Schedule13E-3 as more particularly described below.
The Schedule 13E-3 and the Notice of Share Repurchase Program, including to the extent Item 1 through Item 16 of the Schedule incorporate by reference the information contained in the Notice of Share Repurchase Program, previously were, or hereby are, amended and supplemented as set forth below.
1. In the fourth line on the cover page of the Notice of Share Repurchase Program by deleting “January 31, 2020” and substituting “June 1, 2020” therefor.
2. Adding a new paragraph as the third paragraph on the cover page of the Notice of Share Repurchase Program reading as follows:
“The Program initially was scheduled to expire at 4:00 PM, New York City Time on January 31, 2020. To continue to extend the benefits of the Program to SunLink’s shareholders, the Expiration Time of the Program has been extended until 4:00 P.M., New York City Time, on June 1, 2020, unless further extended or earlier terminated. As of 4:00 P.M. on January 30, 2020, 8,086 Shares have been purchased under the Program for an aggregate purchase price of $ 9,386.
ITEM 1. | SUMMARY TERM SHEET |
The information set forth inSummary Term Sheet—Section 1 of the Notice (“Certain Questions and Answers “), as amended, is incorporated herein by reference. SunLink previously amended in Amendment No. 4 the text in the Summary Term Sheet under the sub-heading “Could the Program or purchases pursuant to the Program entitle the Company to Deregister?” to amend the second sentence thereof and to add three additional sentences, such that the first four sentences under such sub-heading read as follows:
“Yes. Based on recent information, the Company has approximately 300 holders of record and approximately 650 “non-objecting beneficial owners, or NOBOs, who have consented to the disclosure of their beneficial ownership to the Company. If the number of holders of record goes under and remains under 300, the Company would be entitled to Deregister. However, the Company does not know whether the number of holders of record will further change during the pendency of the Program nor does the Company know whether the number of holders of record at the conclusion of the Program will be more than, less than, or equal to 300. Currently, the Company does not expect to take any action to Deregister during the pendency of the Program absent a material reduction below 300 in the number of holders of record or the extended stability of the number of holders of record below 300.”
ITEM 2. | SUBJECT COMPANY INFORMATION |
(a)Name and Address. The name of the issuer is SunLink Health Systems, Inc. The address of its executive offices is 900 Circle 75 Parkway, Suite 1120, Atlanta, Georgia 30339. The telephone number of the executive offices of SunLink is(770) 933-7000.
(b)Securities. The information set forth under “Introduction”in the Notice is incorporated herein by reference.
(c)Trading and Market Price. The Company’s common shares are traded on the NYSE Amex Equities exchange under the symbol “SSY.” The information set forth inSection 8of the Notice (“Certain Company Information; Price Range of Shares”) is incorporated herein by reference.
(d)Dividends. The information set forth in “Section 8 of the Notice (“Certain Company Information; Dividend Policy”) is incorporated herein by reference.
(e)Prior Public Offerings. The information set forth inSection 8 of the Notice (“Certain Company Information; No Recent Prior Public Offerings for Cash”) is incorporated herein by reference.
(f)Prior Stock Purchases. The information set forth inSection 12of the Notice (“Interest of Directors and Executive Officers; Agreements, Transactions, and Arrangements Concerning the Shares”) is incorporated herein by reference.
ITEM 3. | IDENTITY AND BACKGROUND OF FILING PERSON |
(a)Name and address. The Company is the filing person. The Company’s address and telephone number are set forth in Item 2 above. The information set forth inSection 12 of the Notice (“Interest of Directors and Executive Officers; Agreements, Transactions, and Arrangements Concerning the Shares”) is incorporated herein by reference. The information set forth inSection 15 of the Notice (“Miscellaneous”) is incorporated herein by reference.
2